ELVN Enliven Therapeutics, Inc. Insider Trading

CMO Helen Louise Collins sells 40,000 ELVN shares (61.5% of holdings) at $35.10; stock +32.6% in 30 days post-sale

Collins Helen Louise, Chief Medical Officer, sold 40,000 shares at $35.10 on 2026-03-25, reducing her holdings from 65,000 to 25,000 shares—a reduction of 61.5% relative to her pre-transaction position. The sale occurred at $35.10 while the stock currently trades at $38.83, and the stock has risen 32.6% in the 30 days following the sale. Her cross-ticker insider track record shows a 100.00% well-timed rate across 4 prior sells, but outcomes at Enliven specifically are mixed: of the 4 prior trades at ELVN, only 1 was measurable at the 90-day mark and showed a -8.0% return (well-timed). The company reported a net loss of $20,148,000 for its most recent full fiscal year, operating in an unprofitable state with a market cap of $2,322,049,764.98. The large stake reduction and post-sale price appreciation suggest the sale did not precede a material decline, and the unprofitable fundamentals context warrants monitoring whether further executive repositioning occurs.

CMO Helen Collins sold 40,000 ELVN shares for $1.2M at $30.07 avg, reducing stake by 61.5% to 25,000 shares post-transaction.

Collins Helen Louise, Chief Medical Officer, completed 2 separate sales totaling 40,000 shares for $1,202,637.98 on March 9–10, 2026, at a blended average price of $30.07, reducing her holdings from 65,000 to 25,000 shares (a 61.5% reduction in position). The sales occurred at the 52-week high of $30.70, with the stock up 9.3% over 30 days and 63.6% over 90 days. Enliven Therapeutics reported a net loss of $20,148,000 over its most recent full fiscal year; the substantial stake reduction by the CMO at peak valuation levels warrants attention against the company's unprofitable underlying fundamentals. Her prior open-market sale at this ticker on 2024-04-11 showed a 90-day decline of 8.0% following the trade, consistent with a 100% well-timed sell rate in her same-ticker history.

CMO Collins sold 45,000 ELVN shares ($1.2M) on 2026-02-17, reducing stake by 64.3%; stock down 3.3% in 30 days

Collins Helen Louise, Chief Medical Officer, sold 45,000 shares (45.0K shares) of Enliven Therapeutics at $26.17 on 2026-02-17 for $1,177,861.50 ($1.2M), reducing her holdings from 70,000 to 25,000 shares—a -64.3% reduction in her position. The sale occurred while the stock was down 3.3% over the prior 30 days and -11.1% from its 52-week high of $29.42, yet the insider's cross-ticker track record shows a 90d well-timed rate of 100.00%, with her prior ELVN sale on 2024-04-11 followed by -8.0% returns over 90 days. The company is unprofitable with net income of $-20,148,000.00 ($-20.1M), adding fundamental weakness to the technical signal. This substantial reduction in the CMO's stake—particularly from a leader responsible for clinical and medical strategy—warrants investor attention to whether this reflects reassessment of near-term medical or regulatory prospects.

COO Patel sells 48,300 shares at $27.99 avg; post-transaction holding 215,011 shares (-18.3%). Stock up 52.7% in 30 days from $25.75 current.

Patel Anish, Chief Operating Officer, executed 2 separate sales totaling 48,300 shares for $1,351,762.20, reducing his stake by 18.3% to 215,011 shares post-transaction. The sales occurred at a blended average price of $27.99, while the stock currently trades at $25.75—reflecting a 2.4-point decline from the transaction prices. Notably, the stock has rallied 52.7% over the prior 30 days and trades within 1.0% of its 52-week high of $26.00, suggesting elevated valuation momentum at the time of sale. At the same-ticker level, Patel's 5 prior trades at ELVN show a 4-of-5 pattern of well-timed sales on the 90-day horizon, with his most recent sales on 2025-01-07 posting 90-day declines ranging from -26.0% to -27.4%. His cross-ticker track record across 7 open-market sales shows a 57.14% well-timed rate at the 90-day mark. These data points are offset by the company's unprofitability (net income: $-20,148,000.00 in the most recent full fiscal year), which provides fundamental context for the timing of insider sales.

CSO Joseph Lyssikatos sells 132,500 shares for $3.5M at ELVN; blended avg $26.23, stock now $25.03; company unprofitable (-$20.1M net income).

Joseph Lyssikatos, Chief Scientific Officer, executed 4 separate sales totaling 132,500 shares for $3,476,013.95 on January 8–9, 2026, reducing his stake by 14.8% from 897,688 shares to 765,188 shares. The transactions occurred at prices ($20.13, $24.92, $24.90, $29.13) with a blended average of $26.23, slightly above the current price of $25.03, and notably close to the 52-week high of $26.00 achieved during the 30-day window (+48.5% rally). His prior sales at ELVN exhibit a strong timing pattern: 4 of 4 prior trades showed negative 90-day returns, indicating he has historically sold before subsequent declines. The company reported negative net income of $-20,148,000.00 for its most recent full fiscal year, and with a $1.5B market cap, continues to operate unprofitably. The near-peak execution combined with consistent prior success in timing downturns at this ticker warrants scrutiny of any forward guidance or operational headwinds that may have prompted the liquidation.

COO Patel sells 28,367 shares at $24.18 blended average as stock down 9.7% in 30d, company unprofitable with -$23.2M net income.

Anish Patel, CHIEF OPERATING OFFICER, executed 4 separate sales totaling 28,367 shares for $685,868.44 on 2025-01-07 at a blended average price of $24.18, reducing his holdings from 365,011 to 336,644 shares (-7.8%). The current stock price of $21.74 is 26.4% below its 52-week high of $29.55, and the stock has fallen 9.7% over the past 30 days and 22.1% over the past 90 days. At the same-ticker level, Patel's three prior sales at ELVN (on 2024-07-12, 2024-07-15, and 2024-07-16) all showed positive 90-day returns, indicating those prior sales were poorly timed relative to subsequent price performance. The company's fundamental position is challenged: Enliven Therapeutics reported a negative $23.2M net income over its most recent full fiscal year, placing this sale in a context of both near-term equity weakness and sustained unprofitability. The magnitude of this sale (7.8% of pre-transaction holdings in a single day) during a period of significant stock decline and structural losses warrants attention to whether broader strategic or operational headwinds may be emerging.

CSO Joseph Lyssikatos sold 51,145 shares across 4 transactions for $1,437,585.19 at blended average $28.11

Chief Scientific Officer Joseph Lyssikatos executed 4 separate sales totaling 51,145 shares for $1,437,585.19 on October 8–9, 2024, at prices between $27.96 and $28.52. The sales reduced his holdings by 4.8% from 1,067,180 to 1,016,035 shares, representing a material but not complete exit from his position. The timing is noteworthy: the transactions occurred near the 52-week high of $28.21 and the stock now trades at $26.97 (-4.4% from peak), though the stock has appreciated 15.9% over the prior 30 days and 9.0% over the prior 90 days. Against this backdrop, Enliven remains unprofitable with a net loss of $19,950,000 in its most recent full fiscal year, adding context to why a senior scientist would divest shares despite recent price momentum.

CEO Samuel Kintz sold 30.0K shares of ELVN for $841.3K (blended avg $28.07) in 4 separate transactions; stock down 4.4% from 52-week high despite +15.9% 30-day gain.

Samuel Kintz, President and CEO, executed 4 separate sales totaling 29,977 shares on October 8–9, 2024, reducing his holdings from 1,033,793 to 1,003,816 shares (-2.9%). The transactions occurred at prices ranging from $27.95 to $28.53, with a blended average of $28.07. The company reported a full-year net loss of $-19,950,000.00, and the stock is currently trading at $26.97 — below the transaction price and 4.4% below its 52-week high of $28.21. Notably, Kintz's prior sell at ELVN (April 11, 2024) showed negative 90-day returns of -7.9%, aligning with his cross-ticker track record of 100.00% well-timed sells. The current sale follows a +15.9% 30-day rally, placing the stock near recent highs before the recent pullback to current levels.

COO Patel sells 50,000 shares (50.0K shares) at blended $25.06 across 3 transactions; stock near 52-week high ($25.10) despite -$22.7M net loss.

Anish Patel, Chief Operating Officer, conducted 3 separate sales totaling 50,000 shares for $1,252,826.10 over four trading days (July 12–16, 2024), at prices clustered tightly around $25.06. The sales reduced his post-transaction holdings to 344,027 shares, a 12.7% reduction. The timing merits attention: Enliven Therapeutics stock has surged 42.5% over the past 90 days and currently trades at $24.65, just 1.8% below the 52-week high of $25.10—exactly where the COO executed his largest and earliest sales. Concurrently, the company reported a -$22.7M net loss over its most recent full fiscal year. The sale of a significant stake by the COO while the stock approaches its annual peak, amid ongoing unprofitability, presents a pattern for investors to monitor in context of the company's growth trajectory and path to profitability.